Click on the icon on the upper right hand side for the article by Hagit N. Baris, MD, Inbal Kedar, MS, Gabrielle J. Halpern, MB, ChB, Tamy Shohat, MD, Nurit Magal, PhD, Mark D. Ludman, MD and Mordechai Shohat, MD.
IMAJ 2007: 9: December: 847-850
Background: Fanconi anemia complementation group C and Bloom syndrome, rare autosomal recessive disorders marked by chromosome instability, are especially prevalent in the Ashkenazi Jewish community. A single predominant mutation for each has been reported in Ashkenazi Jews: c.711+4A→T (IVS4 +4 A→T) in FACC and BLMAsh in Bloom syndrome. Individuals affected by both syndromes are characterized by susceptibility for developing malignancies, and we questioned whether heterozygote carriers have a similarly increased risk.
Objectives: To estimate the cancer rate among FACC and BLMAsh carriers and their families over three previous generations in unselected Ashkenazi Jewish individuals.
Methods: We studied 42 FACC carriers, 28 BLMAsh carriers and 43 controls. The control subjects were Ashkenazi Jews participating in our prenatal genetic screening program who tested negative for FACC and BLMAsh. All subjects filled out a questionnaire regarding their own and a three-generation family history of cancer. The prevalence rates of cancer among relatives of FACC, BLMAsh and controls were computed and compared using the chi-square test.
Results: In 463 relatives of FACC carriers, 45 malignancies were reported (9.7%) including 10 breast (2.2%) and 13 colon cancers (2.8%). Among 326 relatives of BLMAsh carriers there were 30 malignancies (9.2%) including 7 breast (2.1%) and 4 colon cancers (1.2%). Controls consisted of 503 family members with 63 reported malignancies (12.5%) including 11 breast (2.2%) and 11 colon cancers (2.2%).
Conclusions: We found no significantly increased prevalence of malignancies among carriers in at least three generations compared to the controls.